Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction
Marc Labelle, Robert N. Young(Merck Canada Inc. (Canada)), C. Rochette(Merck Canada Inc. (Canada)), Robert Zamboni(Merck Canada Inc. (Canada)), Nathalie Ouimet(Merck Canada Inc. (Canada)), Thomas R. Jones(University of New Mexico), Robert J. Gordon(University of Windsor), H. Piechuta(Merck Canada Inc. (Canada)), P. Masson(Merck Canada Inc. (Canada)), Daniel Guay(Merck Canada Inc. (Canada)), M. McAuliffe(Merck Canada Inc. (Canada)), Kathleen M. Metters(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yves Gareau(Merck Canada Inc. (Canada)), Yufei Xiang(Merck Canada Inc. (Canada)), D Patrick(United States Military Academy), S. Grossman(United States Military Academy), C. S. McFarlane(Merck Canada Inc. (Canada)), J. Y. GAUTHIER(Merck Canada Inc. (Canada)), Y. LEBLANC(Merck Canada Inc. (Canada)), A. W. Ford‐Hutchinson(Merck Canada Inc. (Canada)), C.B. Pickett(Merck Canada Inc. (Canada)), Nicole Sawyer(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michel Belley(Merck Canada Inc. (Canada))
Cited by 100
Related Papers
The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity
|Journal of Biological Chemistry|1991|1.5k
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818
GLUTATHIONE S-TRANSFERASES: GENE STRUCTURE, REGULATION, AND BIOLOGICAL FUNCTION
|Annual Review of Biochemistry|1989|625